DREAMSeq Trial Clarifies Optimal Sequencing in BRAF V600–Mutant Melanoma

home / oncclub / dreamseq-trial-clarifies-optimal-sequencing-in-braf-v600-mutant-melanoma

Andrew L. Pecora, MD, discusses the phase 3 DREAMseq trial (NCT02224781), which showed that nivolumab (Opdivo) plus ipilimumab (Yervoy) should be administered prior to the combination of a BRAF and MEK inhibitor in patients with advanced BRAF-mutant melanoma.

Michael B. Atkins, MD

Checkpoint Inhibition Prevails as Frontline Standard in BRAF-Mutant Melanoma

October 11th 2022

Findings from the DREAMseq trial indicate that nivolumab plus ipilimumab should be administered prior to the combination of a BRAF and MEK inhibitor in patients with advanced BRAF-mutant melanoma.

Andrew L. Pecora, MD

Dr. Pecora on Key Efficacy Findings from the DREAMSEQ Trial in BRAF-Mutated Melanoma

November 3rd 2022

Andrew L. Pecora, MD, discusses the key efficacy findings from the phase 3 DREAMSEQ trial in BRAF-mutated melanoma.

Andrew L. Pecora, M.D., FACP, CPE, at John Theurer Cancer Center at Hackensack University Medical Center

DREAMSeq Trial Clarifies Treatment Sequencing in BRAF V600–Mutant Melanoma

November 8th 2022

Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations.